Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PANACEA LIFE SCIENCES HOLDINGS, INC.EXDI · Entity 9699 | Director · EXECUTIVE VICE PRESIDENT · 10% owner | September 04, 2018 | September 14, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PANACEA LIFE SCIENCES HOLDINGS, INC.
Report date September 04, 2018 · Filed September 14, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2023-09-04 | Direct | 225,000 |
Reported balance
After 2018-09-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-09-04 · Grant · Acquired 225,000 · Balance 225,000 F1: 178,125 stock options are fully vested with the remainder vesting monthly in equal increments over a 15 month period beginning on October 1, 2018, subject to execution of the Company's standard stock option agreement and continued service as an officer of the Company on each applicable vesting date. F2: Not applicable. |
| Series D Preferred Stock (theSEC Table II · derivative / convertible security | Direct | 11 |
Reported balance
After 2018-09-12 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2018-09-12 · Disposition to issuer · Disposed 16 · Balance 11 F3: On the Transaction Date, the Purchaser entered into an Agreement to unwind and terminate the Series D Subscription Agreement and void the issuance of the Series D Preferred Stock. The sale was approved in advance by the board of directors of the Company and therefore exempt pursuant to Rule 16b-3(e). F4: Each share of Series D automatically converts into 200,000 shares of the Company's common stock upon the consummation of the first offering of the Company's Common Stock, subsequent to the acquisition of the Series D, for which the gross proceeds of the offering exceed $5,000,000. F6: The securities were issued in connection with the repayment of debt, owed by the Company to the Reporting Person, in the amount of $200,000. F5: The Series D has no expiration date. F7: The original Form 4 filed on September 14, 2018, is amended by this Form 4, which corrects Table II Item 9 to show that the Reporting Person beneficially owns 11 shares of Series D following the reported transaction. No other changes have been made to the original Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: 178,125 stock options are fully vested with the remainder vesting monthly in equal increments over a 15 month period beginning on October 1, 2018, subject to execution of the Company's standard stock option agreement and continued service as an officer of the Company on each applicable vesting date.
F2: Not applicable.
F3: On the Transaction Date, the Purchaser entered into an Agreement to unwind and terminate the Series D Subscription Agreement and void the issuance of the Series D Preferred Stock. The sale was approved in advance by the board of directors of the Company and therefore exempt pursuant to Rule 16b-3(e).
F4: Each share of Series D automatically converts into 200,000 shares of the Company's common stock upon the consummation of the first offering of the Company's Common Stock, subsequent to the acquisition of the Series D, for which the gross proceeds of the offering exceed $5,000,000.
F5: The Series D has no expiration date.
F6: The securities were issued in connection with the repayment of debt, owed by the Company to the Reporting Person, in the amount of $200,000.
F7: The original Form 4 filed on September 14, 2018, is amended by this Form 4, which corrects Table II Item 9 to show that the Reporting Person beneficially owns 11 shares of Series D following the reported transaction. No other changes have been made to the original Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2018 Filed Sep 14, 2018 21:25 UTC Amendment | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | Disposition to issuerSeries D Preferred Stock (the · Derivative | 16 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-001393 · form4a-09142018_020937.xml · derivative · entry 2 Ryan Timothy John · CIK 0001714656 · Director · EXECUTIVE VICE PRESIDENT · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11 Underlying: Common Stock · 3,200,000 shares Expires not disclosed F3 · security: On the Transaction Date, the Purchaser entered into an Agreement to unwind and terminate the Series D Subscription Agreement and void the issuance of the Series D Preferred Stock. The sale was approved in advance by the board of directors of the Company and therefore exempt pursuant to Rule 16b-3(e). F4 · derivative.exercise_price: Each share of Series D automatically converts into 200,000 shares of the Company's common stock upon the consummation of the first offering of the Company's Common Stock, subsequent to the acquisition of the Series D, for which the gross proceeds of the offering exceed $5,000,000. F6 · price: The securities were issued in connection with the repayment of debt, owed by the Company to the Reporting Person, in the amount of $200,000. F5 · derivative.expiration_date: The Series D has no expiration date. F7 · balance_after: The original Form 4 filed on September 14, 2018, is amended by this Form 4, which corrects Table II Item 9 to show that the Reporting Person beneficially owns 11 shares of Series D following the reported transaction. No other changes have been made to the original Form 4. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 20:05 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | Disposition to issuerSeries D Preferred Stock (the · Derivative | 16 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-001390 · form4-09142018_040901.xml · derivative · entry 2 Ryan Timothy John · CIK 0001714656 · Director · EXECUTIVE VICE PRESIDENT · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16 Underlying: Common Stock · 3,200,000 shares Expires not disclosed F3 · security: On the Transaction Date, the Purchaser entered into an Agreement to unwind and terminate the Series D Subscription Agreement and void the issuance of the Series D Preferred Stock. The sale was approved in advance by the board of directors of the Company and therefore exempt pursuant to Rule 16b-3(e). F4 · derivative.exercise_price: Each share of Series D automatically converts into 200,000 shares of the Company's common stock upon the consummation of the first offering of the Company's Common Stock, subsequent to the acquisition of the Series D, for which the gross proceeds of the offering exceed $5,000,000. F6 · price: The securities were issued in connection with the repayment of debt, owed by the Company to the Reporting Person, in the amount of $200,000. F5 · derivative.expiration_date: The Series D has no expiration date. Read SEC document |
| September 04, 2018 Filed Sep 14, 2018 21:25 UTC Amendment | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantStock Options (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001415889-18-001393 · form4a-09142018_020937.xml · derivative · entry 1 Ryan Timothy John · CIK 0001714656 · Director · EXECUTIVE VICE PRESIDENT · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2023-09-04 F1 · security: 178,125 stock options are fully vested with the remainder vesting monthly in equal increments over a 15 month period beginning on October 1, 2018, subject to execution of the Company's standard stock option agreement and continued service as an officer of the Company on each applicable vesting date. F2 · price: Not applicable. Read SEC document |
| September 04, 2018 Filed Sep 14, 2018 20:05 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantStock Options (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001415889-18-001390 · form4-09142018_040901.xml · derivative · entry 1 Ryan Timothy John · CIK 0001714656 · Director · EXECUTIVE VICE PRESIDENT · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2023-09-04 F1 · security: 178,125 stock options are fully vested with the remainder vesting monthly in equal increments over a 15 month period beginning on October 1, 2018, subject to execution of the Company's standard stock option agreement and continued service as an officer of the Company on each applicable vesting date. F2 · price: Not applicable. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:05 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantSeries D Preferred Stock (the "Series D") · Derivative | 16 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-001096 · form4-07092018_040701.xml · derivative · entry 6 Ryan Timothy John · CIK 0001714656 · Director · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27 Underlying: Common Stock · 3,200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series D automatically converts into 200,000 shares of the Company's common stock upon the consummation of the first offering of the Company's Common Stock, subsequent to the acquisition of the Series D, for which the gross proceeds of the offering exceed $5,000,000. F3 · price: The securities were issued in connection with the repayment of debt, owed by the Company to the Reporting Person, in the amount of $200,000. F2 · derivative.expiration_date: The Series D has no expiration date. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 22:16 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantSeries D Preferred Stock (the "Series D") · Derivative | 11 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-000482 · form4-03302018_030355.xml · derivative · entry 1 Ryan Timothy John · CIK 0001714656 · Director · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11 Underlying: Common Stock · 2,200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series D automatically converts into 200,000 shares of the Company's common stock upon the consummation of the first offering of the Company's Common Stock, subsequent to the acquisition of the Series D, for which the gross proceeds of the offering exceed $5,000,000. F3 · price: The securities were issued in connection with the repayment of debt, owed by the Company to the Reporting Person, in the amount of $137,500. F2 · derivative.expiration_date: The Series D has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.